Around 70% of ABclonal’s clients have therapeutic goals for their monoclonal antibody development projects. The effects of the therapeutic lead candidates can be evaluated using antibodies recognizing unique variable regions in each candidate, known as anti-idiotype (anti-ID) antibodies. Anti-ID antibodies can be used to identify, neutralize, block, and assess drug-to-analyte binding properties on the target therapeutic antibody.
Useful in anti-drug antibody (ADA) and pharmacokinetic (PK) analysis, anti-idiotype antibodies help provide information about how the drug is absorbed, distributed, metabolized, and eliminated in the patient’s body. These assays and studies help optimize the antibody-based drugs to ensure patients receive safe and effective treatments.
With over 90% success in generating the desired responses in anti-ID antibodies, ABclonal prepares you to successfully detect, identify, and analyze therapeutic drugs to support your upcoming preclinical and downstream clinical trials.
Measure free therapeutic antibody in circulation
Measure total drug levels
Detect bound drug levels only
Proprietary SMab™ platform rapidly identifies blocking and non-blocking antibodies.
Single immunization for both polyclonal and monoclonal anti-ID antibody discovery with high diversity.
Professional hands-on project design and management with fast turnaround time.
800 anti-ID antibodies delivered against a wide range of targets.
6-9 WEEKS
Immunization
2 WEEKS
Splenocyte collection
& single B cell sorting
2 WEEKS
VH/VL cloning &
LEM construction
3 WEEKS
Expression plasmid
construction &
antibody production
Note: Timeline is based on delivery of 20 LEMs and 5 rabbit antibodies.
